Chromocell Therapeutics Corp CHRO 深 滬
等待開盤 07-18 09:30:00 美东时间
1.35
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.35
- 總市值 890.45万
- 52周最高 38.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.50
- 委 比 0.00%
- 總股本 659.59万
- 歷史最高 60.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.50
- 每 手 1
- 風險率 4.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
07-10 20:13
Chromocell Therapeutics Merges and Becomes Pelthos Therapeutics
The latest update is out from Chromocell Therapeutics Corp ( ($CHRO) ). On July...
07-03 05:49
Channel Therapeutics Announces 10-For-1 Reverse Split Ahead Of LNHC Merger, $50M Investment Led By Murchinson
Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock
06-27 21:17
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
Channel Therapeutics Corporation announced a 10-for-1 reverse stock split to increase its share price and meet NYSE American listing requirements ahead of a $50 million merger with LNHC, Inc. The split will reduce the number of outstanding shares from ~6.5 million to ~648,501, effective before market open on July 1, with trading resuming on July 2 under the name "Pelthos Therapeutics Inc." Shareholders' ownership percentages remain unchanged, and...
06-27 13:15
李宁集团与北京体育大学达成战略合作
6月15日，李宁集团与北京体育大学正式签署战略合作协议。北京体育大学党委书记樊战备、校长张剑，李宁品牌创始人、集团董事长李宁，李宁集团副总裁、CHRO宋春涛等出...
06-16 12:10
SYNCHRONY RANKS AS NO. 1 WORKPLACE IN NEW YORK
Fortune magazine and Great Place to Work recognize financial leader for creating a workplace where trust, flexibility and innovation thrive for Tri-State employees STAMFORD, Conn., June 11,...
06-11 19:00
Bausch + Lomb Introduces Zenlens CHROMA HOA Lenses in U.S.
Bausch + Lomb Corporation ( ($BLCO) ) just unveiled an update. Bausch + Lomb ha...
05-14 20:38
EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models
Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and chronic indications.
05-14 19:59
Chromocell Therapeutics Q1 GAAP EPS $(0.32) Misses $(0.31) Estimate
Chromocell Therapeutics (AMEX:CHRO) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 41.82 percent increase over losses of $(0.55) per share
05-14 05:58
